<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mixing nebulized medications: Physical and chemical compatibility</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mixing nebulized medications: Physical and chemical compatibility</h1>
<div class="graphic"><div class="figure"><div class="ttl">Mixing nebulized medications: Physical and chemical compatibility</div><div class="cntnt"><table cellspacing="0"><colgroup span="11" width="9%"></colgroup> <tbody> <tr> <td class="highlight_gray_text"> </td> <td class="subtitle1">Albuterol<br/> (salbutamol)</td> <td class="subtitle1">Albuterol-ipratropium</td> <td class="subtitle1">Arformoterol<sup>¶</sup></td> <td class="subtitle1">Budesonide</td> <td class="subtitle1">Fluticasone<br/> propionate<sup>Δ</sup></td> <td class="subtitle1">Formoterol</td> <td class="subtitle1">Ipratropium bromide</td> <td class="subtitle1">Levalbuterol<br/> (Levosalbutamol)</td> <td class="subtitle1">Revefenacin</td> <td class="subtitle1">Sodium chloride<br/> 7%</td> </tr> <tr> <td><strong>Albuterol (salbutamol)</strong></td> <td class="highlight_gray_text"> </td> <td>NR</td> <td>NR</td> <td>C</td> <td>C*</td> <td>NR</td> <td>C*</td> <td>NR</td> <td>NR</td> <td>C<sup>[1]</sup></td> </tr> <tr> <td><strong>Albuterol-ipratropium</strong></td> <td>NR</td> <td class="highlight_gray_text"> </td> <td>NR</td> <td>C*<sup>[2]</sup></td> <td>NR</td> <td>NR</td> <td>NR</td> <td>NR</td> <td>NR</td> <td>NR</td> </tr> <tr> <td><strong>Arformoterol</strong><sup>¶</sup></td> <td>NR</td> <td>NR</td> <td class="highlight_gray_text"> </td> <td>C<sup>[3]</sup></td> <td>NR</td> <td>NR</td> <td>C<sup>[3]</sup></td> <td>NR</td> <td>NR</td> <td>NR</td> </tr> <tr> <td><strong>Budesonide</strong></td> <td>C</td> <td>C*<sup>[2]</sup></td> <td>C<sup>[3]</sup></td> <td class="highlight_gray_text"> </td> <td>NR</td> <td>C<sup>[3]</sup></td> <td>C</td> <td>C<sup>[4]</sup></td> <td>NR</td> <td>C<sup>◊</sup></td> </tr> <tr> <td><strong>Fluticasone propionate</strong><sup>Δ</sup></td> <td>C*</td> <td>NR</td> <td>NR</td> <td>NR</td> <td class="highlight_gray_text"> </td> <td>NR</td> <td>C*</td> <td>NR</td> <td>NR</td> <td>NR</td> </tr> <tr> <td><strong>Formoterol</strong></td> <td>NR</td> <td>NR</td> <td>NR</td> <td>C<sup>[3]</sup></td> <td>NR</td> <td class="highlight_gray_text"> </td> <td>NR</td> <td>NR</td> <td>C<sup>[5,6]</sup></td> <td>NR</td> </tr> <tr> <td><strong>Ipratropium bromide</strong></td> <td>C*</td> <td>NR</td> <td>C<sup>[3]</sup></td> <td>C</td> <td>C*</td> <td>NR</td> <td class="highlight_gray_text"> </td> <td>C<sup>[4]</sup></td> <td>NR</td> <td>C<sup>[1]</sup></td> </tr> <tr> <td><strong>Levalbuterol (Levosalbutamol)</strong></td> <td>NR</td> <td>NR</td> <td>NR</td> <td>C<sup>[4]</sup></td> <td>NR</td> <td>NR</td> <td>C<sup>[4]</sup></td> <td class="highlight_gray_text"> </td> <td>NR</td> <td>NR</td> </tr> <tr> <td><strong>Revefenacin</strong></td> <td>NR</td> <td>NR</td> <td>NR</td> <td>NR</td> <td>NR</td> <td>C<sup>[5,6]</sup></td> <td>NR</td> <td>NR</td> <td class="highlight_gray_text"> </td> <td>NR</td> </tr> <tr> <td><strong>Sodium chloride 7%</strong></td> <td>C<sup>[1]</sup></td> <td>NR</td> <td>NR</td> <td>C<sup>◊</sup></td> <td>NR</td> <td>NR</td> <td>C<sup>[1]</sup></td> <td>NR</td> <td>NR</td> <td class="highlight_gray_text"> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>Factors other than physicochemical compatibility can alter drug mass delivery profile of medication mixtures. Such factors can include increased volume placed in reservoir and potential for alteration in particle size and character of mixed solutions. Except where compatible ("C") mixtures have an asterisk (*), the effect that mixing of medications has on drug mass delivery profile, relative to separate nebulization, has not been adequately studied.</li>
<li>When mixing nebulized medications, use only freshly opened preservative free PF (ie, single-use) formulations. Mixing should take place immediately before administration.</li>
</ul></div><div class="graphic_footnotes"><p>PF: preservative free; C: compatible; NR: not recommended due to insufficient data or simultaneous use is not clinically warranted.</p>
<p>* For this mixture, study data are available demonstrating that aerosol particle characteristics and drug mass output are similar to those conditions when each drug is nebulized separately.</p>
<p>¶ Not indicated for use in children.</p>
<p>Δ Nebulized formulation of fluticasone is available in many countries other than the United States and Canada.</p>
◊ Physico-chemical compatibility determined with 5.85% hypertonic sodium chloride solution.</div><div class="graphic_reference">References:
<ol>
<li>Fox LM, Foushee JA, Jackson DJ, Watson H. Am J Health System 2011; 68:1032. Visual compatibility of common nebulizer medications with 7% sodium chloride solution. Am J Health System 2011; 68:1032.</li>
<li>Zhang R, Hu J, Deng L, et al. Aerosol Characteristics and Physico-Chemical Compatibility of Combivent® (Containing Salbutamol and Ipratropium Bromide) Mixed with Three Other Inhalants: Budesonide, Beclomethasone or N-Acetylcysteine. Pharmaceutics 2020; 12:78.</li>
<li>Burchett DK, Darko W, Zahra J, et al. Mixing and compatibility guide for commonly used aerosolized medications. Am J Health Syst Pharm 2010; 67:227.</li>
<li>Bonasia PJ, McVicar WK, Bill W, Ong S. Chemical and physical compatibility of levalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium, or acetylcysteine sodium. Respir Care 2008; 53:1716.</li>
<li>Siler TM, Moran EJ, Barnes CN, Crater GD. Safety and efficacy of revefenacin and formoterol in sequence and combination via a standard jet nebulizer in patients with chronic obstructive pulmonary disease: A phase 3b, randomized, 42-day study. Chronic Obstr Pulm Dis 2020; 7:99.</li>
<li>Ngim K, Patel J. Physicochemical stability and compatibility of revefenacin (LAMA) and formoterol fumarate (LABA) inhalation solution admixture. Int J Pharm Compd 2020; 24:242.</li>
</ol>
<p class="extra_spacing_top">Original figure modified for this publication. From: Kamin W, Erdnüss F, Krämer I. Inhalation solutions—Which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers—Update 2013. J Cyst Fibros 2014; 13:243. Table used with the permission of Elsevier Inc. All rights reserved.</p></div><div id="graphicVersion">Graphic 122909 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
